Pacific Biosciences of California (PACB)
(Delayed Data from NSDQ)
$1.30 USD
+0.02 (1.56%)
Updated Jul 3, 2024 01:00 PM ET
After-Market: $1.31 +0.01 (0.77%) 4:34 PM ET
3-Hold of 5 3
D Value F Growth A Momentum D VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
PACB 1.30 +0.02(1.56%)
Will PACB be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for PACB based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for PACB
Reasons to Retain PacBio (PACB) Stock in Your Portfolio Now
PacBio (PACB) and Form Bio to Boost AAV Industry Development
PACB: What are Zacks experts saying now?
Zacks Private Portfolio Services
Pacific Biosciences of California (PACB) Advances While Market Declines: Some Information for Investors
Pacific Biosciences of California (PACB) Stock Sinks As Market Gains: What You Should Know
Reasons to Retain PacBio (PACB) Stock in Your Portfolio
Other News for PACB
Barclays Sticks to Their Hold Rating for Pacific Biosciences (PACB)
Cathie Wood’s top and bottom performing ARKK holdings of H1
PacBio, FormBio collaborate to launch resources for AAV design, analysis
Pacific Biosciences Shareholders Shape Company’s Strategic Future
Jefferies Says Buy These 3 Stocks for More Than Double-Digit Returns